Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | AM0010 (PEG-IL-10) - (Sequoia) | Pancreatic ductal adenocarcinoma (PDAC) | Phase 3 | Subcutaneous | Oncology | |
| Eli Lilly and Company | Orforglipron - (ATTAIN-2) | Obesity | Phase 3 | Data Released | Oral | Endocrinology |
| Eli Lilly and Company | Lanabecestat (AZD3293) - AMARANTH | Early Alzheimer's disease | Phase 3 | Trial Discontinued | Oral | Neurology |
| Eli Lilly and Company | JARDIANCE (empagliflozin) | Heart failure with preserved ejection fraction (HFpEF) | Phase 3 | Oral | Cardiology | |
| Eli Lilly and Company | Taltz (ixekizumab) and Zepbound (tirzepatide) | Active psoriatic arthritis (PsA) and obesity or overweight | Phase 3 | Data Released | Subcutaneous injection | Immunology: Anti-TNF |
| Eli Lilly and Company | Olomorasib in combination with KEYTRUDA (pembrolizumab) LOXO-RAS-20001 - (SUNRAY) | Unresectable advanced or metastatic non-small cell lung cancer (NSCLC) | Phase 3 | Ongoing | Oral | Oncology |
| Eli Lilly and Company | Mirikizumab | Psoriasis | Phase 3 | Subcutaneous | Immunology | |
| Eli Lilly and Company | EMGALITY (galcanezumab) | Chronic and episodic migraine | Phase 3 | Subcutaneous | Neurology |
